Lipopolysaccharide (LPS) Layer

Lipopolysaccharide (LPS) layer also called the outer membrane is the outermost layer present only in the cell wall of gram-negative bacteria.  Braun’s lipoprotein tightly links this outer membrane of the Gram-negative bacteria with the underlying peptidoglycan layer.

Figure: Cell wall of Gram-negative bacteria

This is a second lipid bilayer present in Gram-negative bacteria, the first being cytoplasmic membrane. Unlike cytoplasmic membrane, which is made up of phospholipids only, the LPS layer contains polysaccharides and proteins.

As in peptidoglycan biosynthesis, LPS molecules are assembled at the plasma or inner membrane.

Exception:  Only one Gram-positive bacteria, i.e. Listeria monocytogenes has been found to contain an authentic lipopolysaccharide.

Why LPS is one of the most clinically important molecules in medicine

There is a paradox at the heart of treating gram-negative infections that every medical student and clinician must understand: the very act of killing gram-negative bacteria with antibiotics can, at least initially, make the patient sicker.

When antibiotics kill gram-negative bacteria, the outer membrane disintegrates and large quantities of LPS are released into the bloodstream simultaneously. This sudden LPS flood triggers a massive immune response that can be more dangerous than the infection itself. This is not a theoretical concern — it is the mechanism behind gram-negative septic shock, a clinical emergency with a mortality rate of 20–50% even with aggressive intensive care.

Understanding LPS — what it is, how it triggers this response, and why it is so difficult to neutralise — is essential background knowledge for anyone who will be prescribing antibiotics or managing critically ill patients with gram-negative infections.

Two additional reasons LPS demands clinical attention:

1. Pharmaceutical quality control — every injectable drug and implantable medical device must be tested for LPS contamination before it can be administered to patients. A contaminated intravenous solution can cause immediate pyrogenic reaction (fever, rigors, hypotension) from the LPS. The Limulus Amebocyte Lysate (LAL) test — based on a remarkable property of horseshoe crab blood — is the standard test used globally for this purpose.

2. Vaccine and serotyping tool — the O-antigen component of LPS is so variable between strains that it serves as the basis for identifying and typing many gram-negative pathogens (e.g. E. coli O157:H7, Salmonella Typhimurium 4,5,12:i:1,2). This same O-antigen is a target for some gram-negative vaccines.

Structure and Composition

Figure: Cell wall structure of Gram-negative bacteria (Image source: biorender.com)

The LPS is composed of three distinct units;

1. A phospholipid called Lipid A embeds in a lipopolysaccharide layer in the outer leaflet. Also known as endotoxin, it is responsible for toxic effects (fever and shock). Generally, it is not released until the death of a cell. Exception: Neisseria meningitidis, which over-produces outer membrane fragments.
2. A core polysaccharide of five sugars linked through ketodeoxy-octonate (KDO) to lipid A.
3. O antigen: An outer polysaccharide consisting of up to 25 repeating units of 3-5 sugars. These are hydrophilic in nature. O antigen is highly varied among species. Example: E.coli O157:H7 which causes food poisoning and hemolytic uremic syndrome. O antigens are used to identify certain organisms in microbiology laboratories. O antigens are toxic and account for some of the virulence of certain gram-negative bacteria.

Note: LPS is heat stable and not strongly immunogenic so it cannot be converted to a toxoid.

The analogy that makes LPS structure unforgettable

Think of LPS as a molecular anchor — a three-part flagpole embedded in the outer membrane.

• Lipid A (the anchor) — buried in the outer leaflet of the outer membrane; the hydrophobic fatty acid chains act as a molecular anchor holding the entire structure in place. This is the toxic component — the "toxin" that causes septic shock. Identical to endotoxin.
• Core oligosaccharide (the flagpole base) — a short, non-repeating sugar chain connecting Lipid A to the O-antigen. Relatively conserved within bacterial families.
• O-antigen (the flag) — a long, repeating, highly variable polysaccharide chain extending outward from the bacterial surface into the external environment. Highly species- and strain-specific — like a unique flag that allows identification of each strain.

The critical clinical point: when the flagpole falls (when gram-negative bacteria are killed), the flag and anchor are released together into the bloodstream, and it is the anchor (Lipid A) that activates the immune system with devastating consequences.

Functions of Lipopolysaccharides (LPS) Layer

1. Outer membrane serves as an impermeable barrier to prevent the escape of important enzymes, such as those involved in cell wall growth, from the periplasmic space. It also serves as a barrier to various external chemicals and enzymes that could damage the cell.
2. Outer membrane allows transport of smaller molecules, such as nucleotides, oligosaccharides, monosaccharides, peptides, and amino acids, to pass across via porin channels.
3. Lipopolysaccharide is a pyrogenic (responsible for fever) substance, and also causes endotoxic shock. LPS activates macrophages, leading to the release of TNF-alpha, IL- 1, and IL-6. IL- 1 is a major mediator of fever.
4. Macrophage activation and products lead to tissue damage. Damage to the endothelium from bradykinin-induced vasodilation leads to shock.
5. Coagulation (DIC) is mediated through the activation of Hageman factor (coagulation factor XII).

How LPS Causes Septic Shock — The Complete Mechanism

This is the most important clinical application of LPS knowledge and the section most likely to be tested in clinical examinations.

Step 1 — LPS release When gram-negative bacteria are killed (by antibiotics, complement, or neutrophils), the outer membrane disintegrates. Lipopolysaccharide molecules are released as aggregates called LPS micelles into the circulation.

Step 2 — LPS binding to LBP Free LPS in the bloodstream is bound by LPS-Binding Protein (LBP), an acute-phase protein synthesised by the liver. LBP presents LPS to the immune recognition machinery — it essentially delivers the LPS to the cell surface receptor complex.

Step 3 — CD14 transfer LBP transfers the LPS to CD14 — a glycoprotein present on the surface of macrophages and monocytes (membrane-bound CD14) and also circulating as a soluble protein in blood (soluble CD14). CD14 concentrates LPS and presents it to the main signalling receptor.

Step 4 — TLR4/MD-2 activation CD14 presents LPS to the TLR4/MD-2 complex (Toll-like receptor 4 / myeloid differentiation factor 2) on the macrophage surface. TLR4 is the primary pattern recognition receptor for Lipid A specifically. When TLR4/MD-2 binds LPS, it undergoes dimerisation and triggers intracellular signalling cascades.

Step 5 — Cytokine storm TLR4 activation triggers the NF-κB signalling pathway inside the cell, leading to production and secretion of massive amounts of pro-inflammatory cytokines:

• TNF-α (Tumour Necrosis Factor-alpha) — causes fever, hypotension, increased vascular permeability
• IL-1β (Interleukin-1 beta) — amplifies inflammation, causes fever
• IL-6 (Interleukin-6) — stimulates acute phase response, further inflammation
• IL-8 (Interleukin-8) — recruits neutrophils
• Nitric oxide (NO) — causes profound vasodilation and hypotension

Step 6 — Systemic inflammatory response syndrome (SIRS) The combined effect of these cytokines causes:

• High fever (IL-1, IL-6 act on hypothalamic temperature centre)
• Vasodilation and hypotension — blood pressure drops precipitously
• Increased vascular permeability — plasma leaks from blood vessels into tissues
• Coagulopathy — DIC (disseminated intravascular coagulation) develops
• Multi-organ failure — kidneys, liver, lungs all affected

The antibiotic paradox — why treatment can initially worsen the patient

This is a critically important and frequently tested clinical concept:

When a patient with gram-negative sepsis receives antibiotics, the drugs begin killing the bacteria rapidly. As bacteria die, they release their LPS. If the bacterial load is high at the time of treatment (as it often is in fulminant sepsis), the sudden release of large quantities of LPS from lysing bacteria can cause a Jarisch-Herxheimer-like reaction — a paradoxical worsening of the clinical picture in the first hours after antibiotic administration.

This is one reason why clinicians carefully monitor septic patients in the immediate hours after antibiotic administration, and why some clinical trials have investigated co-administration of LPS-binding agents or anti-inflammatory agents alongside antibiotics in severe gram-negative sepsis.

The key message: Antibiotics kill bacteria, but they do not neutralise LPS. The patient needs both antibiotic therapy AND adequate supportive care to survive the consequences of the LPS released during treatment.

The Limulus Amebocyte Lysate (LAL) Test: Detecting LPS in Drugs and Devices

The remarkable biology behind this test: the horseshoe crab (Limulus polyphemus) has a unique innate immune system. When bacterial LPS enters its bloodstream through a wound, specialised blood cells called amebocytes detect the LPS and immediately release a clotting protein, sealing the wound with a gel to trap the bacteria. Scientists extract and lyse these amebocytes to create the Limulus Amebocyte Lysate (LAL), a reagent so sensitive it gels or changes colour in the presence of vanishingly small quantities of LPS.

This biology is exactly why the LAL test became the global standard for screening every injectable drug, vaccine, and implantable medical device for LPS contamination before it reaches a patient. The full step-by-step LAL procedure, the gel-clot and chromogenic methods, result interpretation, and the recombinant Factor C (rFC) alternative are covered in detail in our Pyrogen and Bacterial Endotoxin Testing Methods article, alongside the rabbit pyrogen test and monocyte activation test.

LPS vs LTA : How Gram-Negative and Gram-Positive Bacteria Cause Sepsis

How to Learn and Remember LPS

The calibration: pure theory — address the "why should I learn this?" question first

LPS is abstract chemistry until you understand its clinical consequences. The three stories below make it concrete.

One sentence that captures the entire clinical relevance

"LPS is the bacterial molecule that kills the patient — not directly, but by tricking the immune system into destroying the patient's own organs in an attempt to fight the infection."

Three clinical stories that make LPS unforgettable

Story 1 — The paradox of successful antibiotic treatment

A patient with gram-negative pneumonia starts IV ceftriaxone at 9am. By 11am, the nursing staff reports that the patient looks worse — higher fever, falling blood pressure, increasing oxygen requirements. The antibiotic is working: bacteria are dying rapidly and releasing their LPS as they lyse. The immune system is responding to this LPS flood with a cytokine storm. The patient needs more vasopressors, not different antibiotics. This is not treatment failure — it is a consequence of successful treatment. Understanding the LPS mechanism prevents the clinical team from panicking and stopping the antibiotics at exactly the wrong moment.

Story 2 — The contaminated IV bag

A hospital pharmacy prepares an intravenous nutrition bag. Unknown to the pharmacist, the water used in preparation was contaminated with gram-negative bacteria which have since been filtered out — but the LPS they released remains in solution, passing through any filter. The patient receives the bag and within 30 minutes develops rigors, a fever of 40°C, and hypotension. The bag is immediately stopped and blood cultures drawn. No bacteria are found in the patient's blood or in the bag — because there are no bacteria. The culprit is LPS alone, dissolved in solution at concentrations sufficient to trigger a systemic pyrogenic reaction. This is why the LAL test exists — to detect LPS even after all bacteria have been removed.

Story 3 — The horseshoe crab that saves lives

Every time a person anywhere in the world receives an intravenous antibiotic, a vaccine, or IV fluids, a horseshoe crab's blood most likely helped certify that it was safe. The Limulus Amebocyte Lysate described above comes from Limulus polyphemus, and it is the reason a manufacturer can say with confidence that a bag of IV fluid contains no detectable endotoxin before it ever reaches a patient. Picture the flagpole falling and LPS flooding into a patient's bloodstream: this crab's blood is what stands between that flood and every vial, bag, and implant that reaches a hospital shelf. Its synthetic descendant, recombinant Factor C, is now stepping into the same role.

Key exam facts in one table

References and further readings

1. Madigan, M. T., Bender, K. S., Buckley, D. H., Sattley, W. M., & Stahl, D. A. (2018). Brock Biology of Microorganisms (15th ed.). Pearson.
2. Tille, P. M. (2017). Bailey & Scott's Diagnostic Microbiology (14th ed.). Mosby Elsevier.
3. VanOtterloo, L. M., & Trent, M. S. (2024). Lipopolysaccharide – a remarkable component of the gram-negative bacterial surface. Microbiology, 170(3). https://doi.org/10.1099/mic.0.001439
4. Rietschel, E. T., Kirikae, T., Schade, F. U., et al. (1994). Bacterial endotoxin: molecular relationships of structure to activity and function. FASEB Journal, 8(2), 217–225. https://doi.org/10.1096/fasebj.8.2.8119492